12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SCY-635: Phase IIa data

Scynexis reported data from a double-blind, placebo-controlled, U.S. Phase IIa trial in 10 patients showing that twice-daily 300 mg oral SCY-635 plus standard of care (SOC; peginterferon alfa-2a and ribavirin) for 4 weeks "restored sensitivity" to peginterferon alfa-2a and ribavirin therapy. After 4 weeks, patients continued SOC for an additional 44 weeks. At week 24, 63%...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >